ScreenIn3D, a spin-out of the University of Strathclyde, has secured a £750,000 seed investment.
It has developed a ‘lab-on-a-chip’ system that allows drug developers to test dozens of cancer therapies on tiny patient-derived tumour samples – offering a faster, easier and more accurate alternative to animal testing.
The funding round was led by TRICAPITAL Angels and included participation from existing investors Gabriel Investments, Scottish Enterprise and the University of Strathclyde – plus German investor Nidobirds Ventures – and private individuals.
Read more HERE.
